Drug intelligence / Profile preview

DPI-385CVS

Development stage: Preclinical
Lead developer: Defender Pharmaceuticals
Modality: Small Molecules
Administration: Intranasal

Overview

DPI-385CVS is an intranasal small molecule formulation of a scopolamine-related muscarinic acetylcholine receptor antagonist being developed by Defender Pharmaceuticals. It is currently in preclinical development for the treatment of Cyclic Vomiting Syndrome (CVS). The drug utilizes Defender's proprietary intranasal delivery technology to provide a rapid-onset anticholinergic effect, targeting the muscarinic receptors involved in the emetic pathway. By delivering the medication intranasally, DPI-385CVS aims to bypass the gastrointestinal tract, which is particularly advantageous for patients experiencing the severe nausea and vomiting episodes characteristic of CVS.

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on DPI-385CVS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPI-385CVS.

Explore the full profile